User:Mr. Ibrahem/Fremanezumab
 A Norwegian syringe of fremanezumab | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Calcitonin gene-related peptide (CGRP) α, β |
| Clinical data | |
| Trade names | Ajovy |
| Other names | TEV-48125, fremanezumab-vfrm |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618053 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Calcitonin gene-related peptide antagonist |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 55–66% |
| Metabolism | Proteolysis |
| Elimination half-life | 30–31 days (estimated) |
| Excretion | Kidney |
| Chemical and physical data | |
| Formula | C6470H9952N1716O2016S46 |
| Molar mass | 145507.54 g·mol−1 |
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines.[6][4] It not a preferred option due to the cost.[6] It is given by injection under the skin.[6][4]
Common side effect include pain and redness at the site of injection.[6] Other side effects may include allergic reactions.[6] Safety in pregnancy and breastfeeding is unclear.[6] It is in the calcitonin gene-related peptide (CGRP) antagonist class of medications.[6]
Fremanezumab was approved for medical use in the United States in 2018,[6] Europe in 2019,[5] and the UK in 2020.[2] In the United States it costs 625 USD per month as of 2021.[8] In the United Kingdom this amount costs the NHS about £450.[7]
References[edit]
- ^ "Fremanezumab (Ajovy) Use During Pregnancy". Drugs.com. 3 October 2018. Archived from the original on 20 October 2020. Retrieved 2 April 2020.
- ^ a b "Fremanezumab". NICE - National Institute for Health and Care Excellence. Archived from the original on 18 November 2021. Retrieved 25 June 2021.
- ^ "Ajovy (fremanezumab) 225 mg Pre-filled Syringe for Injection - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 28 September 2021. Retrieved 27 September 2021.
- ^ a b c "Ajovy- fremanezumab-vfrm injection". DailyMed. 5 February 2020. Archived from the original on 2 January 2022. Retrieved 2 April 2020.
- ^ a b "Ajovy EPAR". European Medicines Agency (EMA). 29 January 2019. Archived from the original on 29 November 2021. Retrieved 2 April 2020.
- ^ a b c d e f g h i j "Fremanezumab-vfrm Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2 January 2022. Retrieved 15 July 2019.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 498. ISBN 978-0857114105.
- ^ "Fremanezumab Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 December 2021.